This study identified the therapeutic potential of TSA, a selective HDAC6 inhibitor, in a PKU mouse model carrying a missense mutation in the PAH gene, resulting in a reduction in plasma phenylalanine levels. This evidence concerns the gene HDAC6 and pulmonary arterial hypertension.